(Q84281205)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21643892%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

title

Incidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDD (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21643892%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

Melvin Berger

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21643892%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

publication date

4 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21643892%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Immunology

3 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21643892%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21643892%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21643892%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

924-926

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21643892%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10875-011-9546-2

3 February 2020

exact match

0 references

cites work

Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels

1 reference

12 December 2020

Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease

1 reference

12 December 2020

Subcutaneous administration of IgG.

1 reference

12 December 2020

Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years.

1 reference

12 December 2020

Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route

1 reference

12 December 2020

Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency

1 reference

12 December 2020

Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies

1 reference

12 December 2020

Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection

1 reference

12 December 2020

Self-infusion programmes for immunoglobulin replacement at home: feasibility, safety and efficacy

1 reference

12 December 2020

Effectiveness of Immunoglobulin Replacement Therapy on Clinical Outcome in Patients with Primary Antibody Deficiencies: Results from a Multicenter Prospective Cohort Study

1 reference

12 December 2020

Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases.

1 reference

12 December 2020

Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies

1 reference

12 December 2020

Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes

1 reference

12 December 2020

Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease

1 reference

12 December 2020

A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously

1 reference

12 December 2020

Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study

1 reference

12 December 2020

Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.

1 reference

12 December 2020

Improved Quality of Life, Immunoglobulin G Levels, and Infection Rates in Patients with Primary Immunodeficiency Diseases during Self-Treatment with Subcutaneous Immunoglobulin G

1 reference

12 December 2020